Onset of multiple sclerosis associated with anti-TNF therapy.
Therapies aimed at inhibiting tumor necrosis factor (TNF), a proinflammatory cytokine implicated in autoimmune disease are effective, especially for rheumatoid arthritis. We report a patient with new onset MS closely associated with the initiation of anti-TNF therapy for juvenile rheumatoid arthritis. It is possible that the inhibition of TNF triggered MS in this individual.
Sicotte
N L
NL
Division of Brain Mapping, UCLA School of Medicine, Los Angeles, CA, USA. nsicotte@ucla.edu
Voskuhl
R R
RR
D000328:Adult; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000175:diagnosis / Q000188:drug therapy*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000175:diagnosis; D009460:Neurologic Examination; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept